BMS-813160, a dual CCR2/CCR5 antagonist, was investigated with nivolumab for advanced renal cell carcinoma to change TAMs and improve anti-PD-1 efficacy in a phase 2 clinical trial, NCT02996110. The gene discussed is CCR2; the disease is renal cell carcinoma.